leucine rich repeat LGI family member 3Genealiases: IDDMDS · LGIL4
Q-omics provides the consensus-scored LGI3 profile across patient tissues and cancer cell-line models. LGI3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, LGI3 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, LGI3 RNA expression shows 17,176 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight DLBC, LUAD, and GBM as cancer lineages where LGI3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LGI3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LGI3 survival associations across molecular data types. LGI3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LGI3 RNA expression–survival associations across cancer types. High LGI3 expression shows unfavorable associations in DLBC, ACC, SKCM, UCEC and STAD, but favorable associations in HNSC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for LGI3 RNA expression.
This table summarizes LGI3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for LGI3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LGI3 shows lower tumor expression in LUAD, THCA, LUSC, COAD and UCEC and higher tumor expression in LIHC. The LUAD box plot shows higher LGI3 RNA expression in normal versus tumor tissue (log2 FC = −5.141, t-test p < 0.001).
This table shows molecular features associated with LGI3 in patient tissues and cancer cell lines. In patient samples, LGI3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LGI3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SKIN.
